{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:26:43Z","timestamp":1782156403413,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR048522"],"award-info":[{"award-number":["T32AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Martha McCrory Professorship","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40674-018-0102-6","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T02:54:05Z","timestamp":1530672845000},"page":"235-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacotherapy Options in the Management of Raynaud\u2019s Phenomenon"],"prefix":"10.1007","volume":"4","author":[{"given":"Alicia M.","family":"Hinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"key":"102_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0022-3999(85)90054-6","volume":"29","author":"RR Freedman","year":"1985","unstructured":"Freedman RR, Ianni P. Effects of general and thematically relevant stressors in Raynaud\u2019s disease. J Psychosom Res. 1985;29:275\u201380.","journal-title":"J Psychosom Res"},{"key":"102_CR2","doi-asserted-by":"crossref","unstructured":"Freedman RR, Ianni P. Role of cold and emotional stress in Raynaud\u2019s disease and scleroderma. Br Med J (Clin Res Ed) [Internet]. 1983;287:1499\u2013502. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6416474\n                      \n                    .","DOI":"10.1136\/bmj.287.6404.1499"},{"key":"102_CR3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/art.1780390717","volume":"39","author":"RR Freedman","year":"1996","unstructured":"Freedman RR, Mayes MD. Familial aggregation of primary Raynaud\u2019s disease. Arthritis Rheum. 1996;39:1189\u201391.","journal-title":"Arthritis Rheum"},{"key":"102_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton C. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754\u201363.","journal-title":"Ann Rheum Dis"},{"key":"102_CR5","doi-asserted-by":"crossref","unstructured":"Kwakkenbos L, Thombs BD. Non-drug approaches to treating Raynaud\u2019s phenomenon. In: Wigley FM, Herrick AL, Flavahan NA, editors. Raynaud\u2019s Phenom. A Guid. to Pathog. Treat. Springer; 2015. p. 299\u2013313.","DOI":"10.1007\/978-1-4939-1526-2_19"},{"key":"102_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/acr.21858","volume":"65","author":"H Gladue","year":"2014","unstructured":"Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud\u2019s phenomenon clinical trials. Arthritis Care Res. 2014;65:630\u20136.","journal-title":"Arthritis Care Res"},{"key":"102_CR7","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.10486","volume":"46","author":"PA Merkel","year":"2002","unstructured":"Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum. 2002;46:2410\u201320.","journal-title":"Arthritis Rheum"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/ard.2009.107706","volume":"69","author":"PP Khanna","year":"2010","unstructured":"Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud\u2019s condition score in patients with Raynaud\u2019s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69:588\u201391.","journal-title":"Ann Rheum Dis"},{"key":"102_CR9","doi-asserted-by":"crossref","unstructured":"Pauling JD, Saketkoo LA, Domsic RT. Patient perceptions of the Raynaud\u2019s Condition Score diary provide insight into its performance in clinical trials of Raynaud\u2019s phenomenon. Arthritis Rheumatol [Internet]. 2018; Available from: \n                      http:\/\/doi.wiley.com\/10.1002\/art.40481\n                      \n                    .","DOI":"10.1002\/art.40481"},{"key":"102_CR10","unstructured":"Pauling JD, Shipley JA, Harris ND, McHugh NJ. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud\u2019s phenomenon and systemic sclerosis. Clin Exp Rheumatol [Internet]. 2012;30:S103\u201315. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22691218\n                      \n                    ."},{"key":"102_CR11","doi-asserted-by":"crossref","unstructured":"Murray A, Pauling JD. Non-invasive methods of assessing Raynaud\u2019s phenomenon. In: Wigley FM, Herrick AL, Flavahan NA, editors. Raynaud\u2019s Phenom. A Guid. to Pathog. Treat. Springer; 2015. p. 199\u2013242.","DOI":"10.1007\/978-1-4939-1526-2_13"},{"key":"102_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/annrheumdis-2015-208857","volume":"75","author":"V Lambrecht","year":"2016","unstructured":"Lambrecht V, Cutolo M, De Keyser F, Decuman S, Ruaro B, Sulli A, et al. Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort. Ann Rheum Dis. 2016;75:1263\u20134.","journal-title":"Ann Rheum Dis"},{"key":"102_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.141437","volume":"42","author":"JD Pauling","year":"2015","unstructured":"Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol. 2015;42:1163\u20138.","journal-title":"J Rheumatol"},{"key":"102_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","volume":"1","author":"AG Franks","year":"1982","unstructured":"Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud\u2019s disease. Lancet. 1982;1:76\u20137.","journal-title":"Lancet"},{"key":"102_CR15","doi-asserted-by":"publisher","unstructured":"Hughes M, Moore T, Manning J, Wilkinson J, Dinsdale G, Roberts C, et al. Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. Microvasc. Res. [Internet]. The Authors; 2017;111:32\u20136. Available from: \n                      https:\/\/doi.org\/10.1016\/j.mvr.2016.12.008\n                      \n                    .","DOI":"10.1016\/j.mvr.2016.12.008"},{"key":"102_CR16","doi-asserted-by":"publisher","unstructured":"Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud\u2019s phenomenon. J Am Acad Dermatol [Internet]. Elsevier Inc; 2018; Available from: \n                      https:\/\/doi.org\/10.1016\/j.jaad.2018.01.043\n                      \n                    .","DOI":"10.1016\/j.jaad.2018.01.043"},{"key":"102_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2017.08.018","volume":"78","author":"X Wortsman","year":"2018","unstructured":"Wortsman X, Del Barrio-D\u00edaz P, Meza-Romero R, Poehls-Risco C, Vera-Kellet C. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: a randomized, double-blind, controlled pilot study. J Am Acad Dermatol. 2018;78:189\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJM198304143081507","volume":"308","author":"RJ Rodeheffer","year":"1983","unstructured":"Rodeheffer RJ, Rommer JA, Wigley FM, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud\u2019s phenomenon. N Engl J Med. 1983;308:880\u20133.","journal-title":"N Engl J Med"},{"key":"102_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S0140-6736(82)91508-2","volume":"5","author":"CD Smith","year":"1982","unstructured":"Smith CD, Mckendry JR. Controlled trial of nifedipine in the treatment of Raynaud\u2019s phenomenon. Lancet. 1982;5:1299\u2013301.","journal-title":"Lancet"},{"key":"102_CR20","doi-asserted-by":"crossref","unstructured":"\u2022 Rirash F, Tingey P, Harding S, Lj M, Tanjong Ghogomu E, Wells G, et al. Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon (review). Cochrane Database Syst Rev. 2017. Systematic review and meta-analysis demonstrating the benefits of calcium channel blocker therapy in the treatment of Raynaud's phenomenon.","DOI":"10.1002\/14651858.CD000467.pub2"},{"key":"102_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"102_CR22","doi-asserted-by":"crossref","unstructured":"Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M. Scleroderma: from pathogenesis to comprehensive management. Second. Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Springer Science; 2017.","DOI":"10.1007\/978-3-319-31407-5"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R Fries","year":"2005","unstructured":"Fries R, Shariat K, Von Wilmowsky H, B\u00f6hm M. Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980\u20135.","journal-title":"Circulation"},{"key":"102_CR24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/ard.2009.116475","volume":"69","author":"CS Brueckner","year":"2010","unstructured":"Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69:1475\u20138.","journal-title":"Ann Rheum Dis"},{"key":"102_CR25","unstructured":"Andrigueti F V, Arismendi MI, Ebbing PCC, Division R. Evaluation of the effect of sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo controlled study F. Clin Exp Rheumatol. 2017;35."},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.30195","volume":"63","author":"AL Herrick","year":"2011","unstructured":"Herrick AL, Van Den Hoogen F, Gabrielli A, Tamimi N, Reid C, O\u2019Connell D, et al. Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63:775\u201382.","journal-title":"Arthritis Rheum"},{"key":"102_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75:1009\u201315.","journal-title":"Ann Rheum Dis"},{"key":"102_CR28","unstructured":"Tadalafil Package Insert [Internet]. 2009. Available from: \n                      https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022332lbl.pdf\n                      \n                    ."},{"key":"102_CR29","doi-asserted-by":"crossref","unstructured":"Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis. J Rheumatol [Internet]. 2009;36:2264\u20138. Available from: \n                      http:\/\/www.jrheum.org\/cgi\/doi\/10.3899\/jrheum.090270\n                      \n                    .","DOI":"10.3899\/jrheum.090270"},{"key":"102_CR30","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","volume":"49","author":"PD Shenoy","year":"2010","unstructured":"Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology. 2010;49:2420\u20138.","journal-title":"Rheumatology"},{"key":"102_CR31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","volume":"172","author":"E Caglayan","year":"2012","unstructured":"Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172:1182\u20134.","journal-title":"Arch Intern Med"},{"key":"102_CR32","unstructured":"FDA. Veletri (epoprostenol) for Injection. Packag. Inser. [Internet]. 2012; Available from: \n                      https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022260s005lbl.pdf\n                      \n                    ."},{"key":"102_CR33","unstructured":"FDA. Orenitram (TM) (treprostinil) extended release. Packag. Inser. [Internet]. 2013; Available from: \n                      https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203496s000lbl.pdf\n                      \n                    ."},{"key":"102_CR34","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/art.40242","volume":"69","author":"CP Denton","year":"2017","unstructured":"Denton CP, Hachulla \u00c9, Riemekasten G, Schwarting A, Frenoux JM, Frey A, et al. Efficacy and safety of selexipag in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 2017;69:2370\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"102_CR35","first-page":"333","volume":"26","author":"M Colaci","year":"2008","unstructured":"Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Rossi R, Modena MG, et al. Cardiovascular risk and prostanoids in systemic sclerosis. Clin Exp Rheumatol. 2008;26:333\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"102_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/1060028016660324","volume":"50","author":"JE Cruz","year":"2016","unstructured":"Cruz JE, Ward A, Anthony S, Chang S, Bae H(B), Hermes-DeSantis ER. Evidence for the use of epoprostenol to treat Raynaud\u2019s phenomenon with or without digital ulcers. Ann Pharmacother. 2016;50:1060\u20137.","journal-title":"Ann Pharmacother"},{"key":"102_CR37","doi-asserted-by":"crossref","unstructured":"Belch JJ, Drury JK, Capell H, Forbes CD, Newman P, Mckenzie F, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud\u2019s syndrome: a double-blind controlled trial. Lancet. 1983:313\u20135.","DOI":"10.1016\/S0140-6736(83)91624-0"},{"key":"102_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/00005344-199509000-00007","volume":"26","author":"K Kingma","year":"1995","unstructured":"Kingma K, Wollersheim H, Thien T. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud\u2019s phenomenon: the acute vasodilatory effect is not sustained. J Cardiovasc Pharmacol. 1995;26:388\u201393.","journal-title":"J Cardiovasc Pharmacol"},{"key":"102_CR39","doi-asserted-by":"crossref","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, et al. Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev [Internet]. 1998; Available from: \n                      http:\/\/doi.wiley.com\/10.1002\/14651858.CD000953\n                      \n                    .","DOI":"10.1002\/14651858.CD000953"},{"key":"102_CR40","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"FM Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41:670\u20137.","journal-title":"Arthritis Rheum"},{"key":"102_CR41","doi-asserted-by":"crossref","unstructured":"Black CM, Halkier-S\u00f8rensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al. Oral iloprost in Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol [Internet]. 1998;37:952\u201360. Available from: \n                      http:\/\/rheumatology.oxfordjournals.org\/cgi\/reprint\/37\/9\/952%5Cnpapers:\/\/454c05cc-adc5-4015-bf6b-be819de563dc\/Paper\/p2432\n                      \n                    .","DOI":"10.1093\/rheumatology\/37.9.952"},{"key":"102_CR42","doi-asserted-by":"crossref","unstructured":"Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, Wise R, Boin F, Seibold JR, Wigley F, Rollins KD Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. Arthritis Res Ther [Internet]. 2013;15:1\u201310. Available from.","DOI":"10.1186\/ar4216"},{"key":"102_CR43","unstructured":"Seibold JR, Wigley FM, Schiopu E, Denton CP, Silver RM, Steen VD, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum. 2011;63"},{"key":"102_CR44","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3899\/jrheum.151437","volume":"43","author":"AA Shah","year":"2016","unstructured":"Shah AA, Schiopu E, Chatterjee S, Csuka ME, Frech T, Goldberg A, et al. The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil. J Rheumatol. 2016;43:1665\u201371.","journal-title":"J Rheumatol"},{"key":"102_CR45","doi-asserted-by":"crossref","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Gali\u00e8 N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med [Internet]. 2015;373:2522\u201333. Available from: \n                      http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1503184\n                      \n                    .","DOI":"10.1056\/NEJMoa1503184"},{"key":"102_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.apha.2016.05.002","volume":"77","author":"M Houde","year":"2016","unstructured":"Houde M, Desbiens L, D\u2019Orl\u00e9ans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. Adv Pharmacol. 2016;77:143\u201375.","journal-title":"Adv Pharmacol"},{"key":"102_CR47","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1016\/j.bmcl.2016.06.014","volume":"26","author":"C Boss","year":"2016","unstructured":"Boss C, Bolli MH, Gatfield J. From bosentan (Tracleer\u00ae) to macitentan (Opsumit\u00ae): the medicinal chemistry perspective. Bioorg Med Chem Lett. 2016;26:3381\u201394.","journal-title":"Bioorg Med Chem Lett"},{"key":"102_CR48","unstructured":"Actelion Pharmaceuticals US. Tracleer\u00ae (Bosentan). Prescribing information. Packag. Inser. [Internet]. 2009; Available from: \n                      http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021290s012lbl.pdf\n                      \n                    ."},{"key":"102_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/kel290","volume":"45","author":"N Selenko-Gebauer","year":"2006","unstructured":"Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud\u2019s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology. 2006;45:45\u20138.","journal-title":"Rheumatology"},{"key":"102_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/039463201002300422","volume":"23","author":"N Giordano","year":"2010","unstructured":"Giordano N, Puccetti L, Papakostas P, Di Pietra N, Bruni F, Pasqui AL, et al. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int J Immunopathol Pharmacol. 2010;23:1185\u201394.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"102_CR51","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00296-008-0789-z","volume":"29","author":"M Funauchi","year":"2009","unstructured":"Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int. 2009;29:769\u201375.","journal-title":"Rheumatol Int"},{"key":"102_CR52","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/ard.2007.073684","volume":"66","author":"ME Hettema","year":"2007","unstructured":"Hettema ME, Zhang D, Bootsma H, Kallenberg CGM. Bosentan therapy for patients with severe Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis. 2007;66:1398\u20139.","journal-title":"Ann Rheum Dis"},{"key":"102_CR53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","volume":"49","author":"VA Nguyen","year":"2009","unstructured":"Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology. 2009;49:583\u20137.","journal-title":"Rheumatology"},{"key":"102_CR54","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3899\/jrheum.100358","volume":"37","author":"E Rosato","year":"2010","unstructured":"Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol. 2010;37:2531\u20139.","journal-title":"J Rheumatol"},{"key":"102_CR55","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985\u201393.","journal-title":"Arthritis Rheum"},{"key":"102_CR56","doi-asserted-by":"crossref","unstructured":"\u2022 Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32\u20138.Study demonstrated that subjects treated with bosentan had a reduction in new digital ulcers compared with placebo.","DOI":"10.1136\/ard.2010.130658"},{"key":"102_CR57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2014.04.028","volume":"71","author":"L Chung","year":"2014","unstructured":"Chung L, Ball K, Yaqub A, Lingala B, Fiorentino D. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol. 2014;71:400\u20131.","journal-title":"J Am Acad Dermatol"},{"key":"102_CR58","doi-asserted-by":"crossref","unstructured":"Bose N, Bena J, Chatterjee S. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial. Arthritis Res Ther [Internet]. 2015;17:44. Available from: \n                      http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4384235&tool=pmcentrez&rendertype=abstract\n                      \n                    .","DOI":"10.1186\/s13075-015-0558-9"},{"key":"102_CR59","doi-asserted-by":"publisher","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","volume":"7","author":"J Gatfield","year":"2012","unstructured":"Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7:e47662.","journal-title":"PLoS One"},{"key":"102_CR60","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1001\/jama.2016.5258","volume":"315","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Merkel PA, Krieg TM, Le Brun FO, Marr A, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: dual-1 and dual-2 randomized clinical trials. JAMA. 2016;315:1975\u201388.","journal-title":"JAMA"},{"key":"102_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3899\/jrheum.131284","volume":"41","author":"M Cutolo","year":"2014","unstructured":"Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, et al. Long term treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol. 2014;41:881\u20136.","journal-title":"J Rheumatol"},{"key":"102_CR62","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/1753193413516242","volume":"39","author":"L Uppal","year":"2014","unstructured":"Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud\u2019s syndrome associated with scleroderma. J Hand Surg Eur Vol. 2014;39:876\u201380.","journal-title":"J Hand Surg Eur Vol"},{"key":"102_CR63","doi-asserted-by":"crossref","unstructured":"Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol [Internet]. 2017;69:1661\u20139. Available from: \n                      http:\/\/doi.wiley.com\/10.1002\/art.40123\n                      \n                    .","DOI":"10.1002\/art.40123"},{"key":"102_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejvs.2006.01.017","volume":"32","author":"TH Thune","year":"2006","unstructured":"Thune TH, Ladegaard L, Licht PB. Thoracoscopic sympathectomy for Raynaud\u2019s phenomenon-a long term follow-up study. Eur J Vasc Endovasc Surg. 2006;32:198\u2013202.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"102_CR65","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.jtcvs.2006.12.055","volume":"133","author":"P Maga","year":"2007","unstructured":"Maga P, Kuzdza\u0142 J, Nizankowski R, Szczeklik A, S\u0142adek K. Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. J Thorac Cardiovasc Surg. 2007;133:1428\u201333.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"102_CR66","unstructured":"Karapolat S, Turkyilmaz A, Tekinbas C. Effects of endoscopic thoracic sympathectomy on Raynaud\u2019s disease. J Laparoendosc Adv Surg Tech [Internet]. 2018;0:lap.2017.0634. Available from: \n                      http:\/\/online.liebertpub.com\/doi\/10.1089\/lap.2017.0634\n                      \n                    ."},{"key":"102_CR67","doi-asserted-by":"publisher","unstructured":"Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy. J Hand Surg Am [Internet]. Elsevier Inc.; 2009;34:1454\u201360. Available from: \n                      https:\/\/doi.org\/10.1016\/j.jhsa.2009.05.003\n                      \n                    .","DOI":"10.1016\/j.jhsa.2009.05.003"},{"key":"102_CR68","first-page":"450","volume":"16","author":"JR Soberon","year":"2016","unstructured":"Soberon JR, Tuxillo TM, Gethers CC, Smith TA, Davis WE. Axillary block-induced chemical sympathectomy in the setting of digital ischemia. Ochsner J. 2016;16:450\u20136.","journal-title":"Ochsner J"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40674-018-0102-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-018-0102-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-018-0102-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:51:05Z","timestamp":1589673065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40674-018-0102-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s40674-018-0102-6","relation":{},"ISSN":["2198-6002"],"issn-type":[{"value":"2198-6002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"4 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alicia M. Hinze declares that she has no conflict of interest. Fredrick M. Wigley declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}